Recommended Articles
Deals & Exits

Viatris Completes $1.69 Billion Pacira Acquisition After Two-Thirds of Shares Tender

By Angeled · November 19, 2026 · Deals & Exits
Viatris Completes $1.69 Billion Pacira Acquisition After Two-Thirds of Shares Tender
Viatris Completes $1.69 Billion Pacira Acquisition After Two-Thirds of Shares Tender

On November 17, 2026, Viatris Inc. completed its acquisition of Pacira BioSciences, Inc., closing a $36.50-per-share cash deal that had been announced just six weeks earlier. The tender offer expired on November 16, 2026, with 32,929,780 shares validly tendered, representing approximately 66.46 percent of Pacira's shares outstanding. Viatris then completed a short-form merger under Delaware law without a Pacira stockholder vote, leaving Pacira as a wholly owned subsidiary. The total funds needed to pay for the shares and repay certain Pacira indebtedness were approximately $1.69 billion, funded by Viatris using cash on hand and short-term borrowings. Pacira's shares will be delisted from the Nasdaq Global Select Market.

The deal brings Viatris two established non-opioid pain treatments, EXPAREL and ZILRETTA, and a commercial business that generated $746 million in revenue and $177 million in adjusted EBITDA in the twelve months ended June 30, 2026. Viatris expects the acquisition to contribute $90 million to $100 million in revenue in the stub period from November 17 through December 31, 2026. For a company built from the combination of Mylan and Pfizer's Upjohn business, the Pacira deal is a deliberate step toward a larger innovative-medicines portfolio — and one of the fastest tender-offer acquisitions of the year, moving from signed merger agreement to closed deal in forty days.

How the deal closed

The transaction moved on a tight timetable. Viatris and Pacira signed their Agreement and Plan of Merger on October 8, 2026. Viatris's wholly owned subsidiary, Peach Purchaser Sub Inc., commenced a tender offer on October 30, 2026, to purchase all outstanding Pacira common shares at $36.50 per share in cash, net of applicable withholding taxes and without interest. The offer and related withdrawal rights expired at one minute past 11:59 p.m. Eastern Time on November 16, 2026.

At expiration, 32,929,780 shares had been validly tendered and not validly withdrawn, representing approximately 66.46 percent of Pacira's shares outstanding immediately prior to expiration. That level comfortably exceeded the minimum tender condition, which is typically set at a majority of outstanding shares. With the condition satisfied, Viatris accepted the tendered shares for payment on November 17 and moved immediately to the second step of the transaction.

Following consummation of the tender offer, the remaining conditions to the merger were satisfied or waived, and the parties completed the merger on November 17, 2026. Peach Purchaser Sub merged with and into Pacira under Section 251(h) of the Delaware General Corporation Law, a provision that permits a merger without a stockholder vote when the buyer has acquired a majority of shares through a tender offer. Pacira survived the merger as a wholly owned subsidiary of Viatris. At the effective time, each outstanding Pacira share not held by the company, Viatris, or dissenting stockholders was converted into the right to receive the $36.50 offer price in cash.

The price and the math

The headline number for the deal is approximately $1.69 billion, but that figure deserves a careful reading. According to Viatris's Form 8-K filed on November 17, 2026, the aggregate amount to be paid in the offer and the merger is approximately $1.69 billion, excluding related fees and expenses. A separate disclosure states that the total funds needed to pay for the shares and repay certain Pacira indebtedness were approximately $1.69 billion. In other words, the $1.69 billion covers both the equity purchase price and the repayment of some of Pacira's debt.

The equity value of the deal at announcement was lower — roughly $1.65 billion, based on the $36.50 per-share price and Pacira's share count. The difference between the two figures is the debt repayment folded into the total funds. Both numbers are accurate; they simply measure different things. The $1.65 billion is what shareholders receive. The $1.69 billion is what Viatris must fund in total to close the transaction and clean up the target's balance sheet. For founders and investors tracking deal sizes, the distinction matters: the headline total is not the same as the equity value, and the gap is the cost of assuming the target's obligations.

The $36.50 per-share price was paid entirely in cash. Viatris funded the transaction with cash on hand and short-term borrowings, rather than issuing new shares or raising long-term debt at closing. That choice keeps the deal simple for Pacira's shareholders, who receive cash rather than a mix of cash and stock, and it reflects Viatris's balance-sheet capacity. It also avoids diluting existing Viatris shareholders, which matters for a company whose stock has faced pressure in recent years. A cash deal funded from the balance sheet sends a clear signal: Viatris believes it can afford this acquisition without asking its own investors for more capital. The company had previously said the acquisition was expected to be immediately accretive to its financial guidance metrics and to have minimal impact on gross leverage — a claim that the cash-and-short-term-borrowing structure supports, though the completion announcement provided no updated earnings contribution, borrowing amount, interest cost, or leverage figure.

What Viatris is buying

Pacira BioSciences is a New Jersey-based biopharmaceutical company focused on non-opioid pain management. Its commercial portfolio centers on two products. EXPAREL is a long-acting local anesthetic used for postsurgical pain control. It is a liposomal formulation of bupivacaine that releases the drug slowly at the surgical site, giving patients days of pain relief from a single administration. ZILRETTA is an extended-release injectable treatment for osteoarthritis knee pain, delivering a corticosteroid directly into the knee joint over a period of weeks.

Both products address the same structural problem: the medical system's reliance on opioids for pain management. Postsurgical pain and osteoarthritis are among the most common reasons patients are prescribed opioids, and the long-running opioid crisis has made physicians, hospitals, and payers eager for alternatives. Non-opioid treatments that can keep patients comfortable without narcotics have become a priority in surgical and orthopedic care, and EXPAREL in particular has built a substantial commercial presence in operating rooms across the United States.

For Viatris, the acquisition adds two marketed products with established sales to a portfolio that has historically leaned on generic and off-patent medicines. The company has been working to build its innovative-medicines business — branded products with patent protection and growth potential — as a counterweight to the pricing pressure in generics. Pacira's products fit that strategy precisely: they are differentiated, they serve large patient populations, and they operate in a therapeutic area where demand is rising as health systems look for ways to reduce opioid use.

Pacira by the numbers

The financial case for the deal rests on Pacira's existing commercial performance. For the twelve months ended June 30, 2026, Pacira reported $746 million in revenue and $177 million in adjusted EBITDA. That implies an adjusted EBITDA margin of roughly 24 percent — a healthy level for a commercial-stage biopharmaceutical company, and one that suggests the business can contribute meaningfully to Viatris's cash generation from the start.

Viatris expects the acquisition to add $90 million to $100 million of revenue in the stub period from November 17 through December 31, 2026 — roughly six weeks of ownership. Annualized, that run rate is consistent with Pacira's reported trailing revenue, which gives the guidance credibility. It also implies that Viatris is paying roughly 2.2 times trailing revenue for the business, a modest multiple for a company with marketed products and a positive EBITDA margin.

The speed of the deal also matters for the numbers. Because the transaction closed in mid-November, Viatris captures the benefit of Pacira's fourth-quarter sales, traditionally a strong period for surgical products as patients schedule procedures before year-end insurance deductibles reset. The stub-period revenue guidance suggests Viatris expects to capture that seasonal strength in its own fourth-quarter results. It also means the acquisition begins contributing to Viatris's reported results almost immediately, with no long waiting period between announcement and financial impact — a feature of the tender-offer structure that shareholders on both sides can appreciate.

What the completion announcement did not provide is an updated view of earnings contribution, borrowing costs, or leverage. Viatris had previously said the deal would be immediately accretive to its guidance metrics with minimal impact on gross leverage, but the filing offers no figures to test that claim against. Investors will look to Viatris's next earnings report for the first concrete evidence of how the acquisition affects the combined company's profitability and debt load.

The convertible notes wrinkle

Every acquisition of a public company carries complications beyond the share purchase, and Pacira's capital structure supplied one. Pacira had $287.5 million in aggregate principal amount of 2.125 percent Convertible Senior Notes due 2029 outstanding. The closing of the merger triggered terms under those notes, which were covered by a First Supplemental Indenture dated November 17, 2026.

Following the merger, the notes now convert solely into cash at $36.50 multiplied by the conversion rate, rather than into shares of Pacira stock that no longer trade. A make-whole provision applies through January 8, 2027, paying $1,103.8914 per $1,000 of principal, after which the amount steps down to $922.5448 per $1,000. These mechanics are standard for convertible notes in a cash acquisition, but they add a layer of cost and complexity to the transaction — and they explain part of the gap between the equity value and the total funds Viatris needed to close.

The treatment of the notes also illustrates why the $1.69 billion figure includes debt repayment. When a buyer acquires a company with outstanding convertible debt, the notes do not simply disappear. They must be addressed through conversion, redemption, or assumption, and the cash required to settle them is part of the true cost of the deal. Viatris's disclosure that total funds of about $1.69 billion were needed for share purchases and certain debt repayment reflects that reality.

Why Viatris wanted this deal

Viatris was formed in 2020 through the combination of Mylan and Pfizer's Upjohn unit, creating one of the world's largest suppliers of generic and off-patent medicines. The company has spent the years since working to rebalance its portfolio toward innovative, branded products with stronger pricing power and growth. The Pacira acquisition is the latest and one of the largest steps in that direction.

The strategic logic is straightforward. Generic medicines face relentless price erosion as competitors enter and payers push for lower costs. Branded products with clinical differentiation — like a long-acting local anesthetic that reduces opioid use — can hold their prices and grow. EXPAREL and ZILRETTA also give Viatris a foothold in hospital and surgical channels, where it can build relationships with the physicians and administrators who decide which products get used in operating rooms.

There is also a policy tailwind. Governments and health systems in the United States and elsewhere have spent years trying to reduce opioid prescribing, and non-opioid pain management is now a stated priority in surgical care guidelines and hospital quality programs. A company that owns two established non-opioid products is well positioned to benefit as those policies tighten. The acquisition is, in effect, a bet that the shift away from opioids in postsurgical and orthopedic care will continue — and that the products best positioned to replace them will command a premium.

The deal also gives Viatris something harder to quantify but strategically important: a commercial team that knows how to sell into hospitals. Generic medicines are typically sold through distributors and procurement contracts, with limited direct contact with prescribers. Branded surgical products require a field force that calls on surgeons, anesthesiologists, and hospital pharmacy committees — a different kind of selling, with different relationships and different skills. Pacira's commercial organization brings that capability in-house. If Viatris wants to acquire or develop more hospital products in the future, it now has the team to sell them. That infrastructure value does not appear in the revenue multiple, but it is a real part of what the $1.69 billion buys.

What happens next

With the merger complete, Pacira is a wholly owned subsidiary of Viatris, and its shares will be delisted from the Nasdaq Global Select Market. The company's leadership changed at the effective time: all nine directors, including chief executive Frank D. Lee, and six officers exited, and John Miraglia and Michael Rainerman now run the surviving company. The clean break is typical of a cash acquisition, where the buyer installs its own management rather than retaining the target's team.

The immediate task is integration. Viatris must fold Pacira's commercial organization, its manufacturing and supply chain, and its regulatory obligations into its own operations without disrupting sales of EXPAREL and ZILRETTA. The products are sold to hospitals and physicians who depend on reliable supply, so any disruption in the transition would show up quickly in revenue. Viatris's experience integrating large acquisitions — including the Mylan-Upjohn combination itself — gives it a playbook, but each integration carries its own risks.

The financial reporting will be the first public test. Viatris's fourth-quarter results will include the stub-period revenue of $90 million to $100 million it has guided, and investors will look for the earnings contribution, the borrowing costs, and any update on leverage. The company will also need to address Pacira's pipeline and research programs, which have received less attention than the commercial products but represent the longer-term value of the acquisition.

The convertible notes will also require attention in the months ahead. The make-whole provision that pays $1,103.8914 per $1,000 of principal runs through January 8, 2027, after which the amount steps down to $922.5448. Noteholders deciding whether to convert will weigh the cash conversion value against holding the notes to maturity in 2029, and Viatris will need to manage the resulting cash outflows. The notes are a manageable obligation for a company of Viatris's size, but they are a reminder that the true cost of an acquisition extends beyond the share price and that the financing work continues after the closing press release.

The wider deal context

The Pacira acquisition is part of a broader wave of pharmaceutical consolidation, in which large companies are buying commercial-stage assets to fill gaps in their portfolios. The pattern is familiar: a company with a strong balance sheet and a need for growth buys a smaller company with marketed products and positive cash flow, paying a modest multiple of revenue and funding the deal with cash and short-term debt. The Pacira deal fits that template closely.

What distinguishes it is speed. Forty days from signed merger agreement to closed deal is fast for a public-company acquisition, and it reflects the efficiency of the tender-offer structure. By launching a tender offer rather than seeking a stockholder vote, Viatris avoided the weeks of proxy preparation and shareholder meetings that a traditional merger requires. The Section 251(h) short-form merger then let it squeeze out the remaining shareholders without a vote. For founders and investors, the structure is a reminder that the fastest path to closing a public acquisition is often a tender offer with a majority minimum condition — provided the price is high enough to draw a majority of shares.

The deal also highlights the value of marketed products in the current market. Pacira's $746 million in trailing revenue and positive EBITDA made it an attractive target at a multiple that looks modest by biotechnology standards, where pre-revenue companies routinely command billion-dollar valuations. In a market that has grown more skeptical of unproven science, cash-generating commercial assets have become the most sought-after acquisition targets. Viatris's purchase of Pacira is a bet on that logic — that proven products, sold to real customers, are worth more than the promise of a pipeline.

For founders building commercial-stage biopharmaceutical companies, the Pacira outcome is instructive. The company did not sell on a breakthrough pipeline or a platform story. It sold on revenue, margins, and two products that physicians already use. The $36.50 per-share price and the $1.69 billion total reflect the value of a business that works today, not one that might work tomorrow. In a funding environment where venture investors have pulled back from early-stage biotechnology, that is a useful signal: companies that reach commercial scale with real products can still command attractive exits, even when the broader market is cautious. The tender offer's 66.46 percent participation rate — well above the minimum condition — suggests shareholders agreed.

Angeled.com connects founders with investors.

SEC EDGAR
Panabee
Kalkine
Readthrough
Viatris

Read Next